Royal Philips has today announced the introduction of its VeriSight Pro 3D intracardiac echocardiography (ICE) catheter in Europe. Building on its success in the USA, VeriSight Pro brings real-time 3D imaging directly inside the heart, helping physicians perform procedures with greater clarity—as detailed in a Philips press release.
Designed for procedures like transcatheter valve implantation (TAVI) and left atrial appendage closure (LAAC), VeriSight Pro offers high-resolution 2D and 3D visualisation directly within the heart chambers. This enables confident clinical decision-making in structural heart and electrophysiology interventions, while removing the need for general anaesthesia and its associated risks, Philips claims.
“With VeriSight Pro 3D ICE, we now have the ability to see detailed cardiac anatomy from inside the heart in real time,” said Jörg Hausleiter (Ludwig-Maximilians-Universität [LMU], Munich, Germany). “This helps streamline our workflows and makes complex procedures more accessible to patients who may not tolerate more invasive imaging approaches.”
VeriSight Pro is described by Philips as a “pioneering innovation”—a miniaturised ultrasound probe, approximately 3mm in diameter, embedded at the tip of a thin, steerable catheter. This tiny device can be navigated through the vascular system and into the heart chambers, where it delivers high-quality 2D and 3D images in real time. Imaging the heart from within, with control over the scan angle, opens “entirely new possibilities” for guiding structural heart interventions, the company claims, also noting that physicians can assess anatomy, guide device placement, and confirm procedural results, all from a single access point and without the need for more invasive imaging techniques.
According to Philips, as the first ICE catheter to miniaturise the same 3D imaging technology used in transoesophageal echocardiography (TEE), VeriSight Pro helps address key barriers in delivering efficient, scalable care, from patient tolerance to resource availability in interventional suites.
“VeriSight Pro reflects our ongoing commitment to delivering clinically relevant innovations that enhance precision, reduce procedure complexity, and improve the care experience,” said Stacy Beske, business leader of image-guided therapy devices at Philips. “Its availability in Europe is an important milestone in helping more patients benefit from image-guided, minimally invasive heart procedures, while supporting care teams with integrated solutions that adapt to the way they work.”
Philips will highlight the VeriSight Pro 3D ICE catheter and its role in structural heart interventions this week at EuroPCR 2025 (20–23 May, Paris, France).
